Evidence map›Paper›PMID 34859258›Full record

ArticleOncology reports2022

Downregulation of lncRNA

Yutaro Fujii, Vishwa Jeet Amatya, Kei Kushitani, Rui Suzuki, Yuichiro Kai, Takahiro Kambara, Yukio Takeshima

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yutaro FujiiDepartment of Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734‑8551, Japan.
Vishwa Jeet AmatyaDepartment of Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734‑8551, Japan.
Kei KushitaniDepartment of Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734‑8551, Japan.
Rui SuzukiDepartment of Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734‑8551, Japan.
Yuichiro KaiDepartment of Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734‑8551, Japan.
Takahiro KambaraDepartment of Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734‑8551, Japan.
Yukio TakeshimaDepartment of Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734‑8551, Japan.
Hiroshima University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant mesothelioma is a highly aggressive tumor, and an effective strategy for its treatment is not yet available. Long non‑coding RNAs (lncRNAs) have been reported to be associated with various biological processes, including the regulation of gene expression of cancer‑related pathways. Among various lncRNAs, plasmacytoma variant translocation 1 (

Indexed as

Gene Expression Regulation, NeoplasticCell CycleCell Line, TumorCell MovementCell ProliferationDown-RegulationForkhead Box Protein M1HumansMesothelioma, MalignantRNA, Long NoncodingForkhead Box Protein M1FOXM1 protein, humanPVT1 long-non-coding RNA, humanRNA, Long NoncodingFOXM1long non‑coding RNAmalignant mesotheliomaplasmacytoma variant translocation 1small interfering RNA

Identifiers

PMID34859258
PMCPMC8674703
OpenAlexW3215930249

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.